Citigroup Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)

Market Context

BioMarin Pharmaceutical Inc. operates in the Healthcare sector. The stock currently trades at $60.00 with a market capitalization of $10.2B. The stock has gained 1.2% over the past 52 weeks.

Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BioMarin Pharmaceutical Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for BioMarin Pharmaceutical Inc.

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 16, 2026	Citigroup	Buy	N/A
Jul 07, 2026	RBC Capital	Sector Perform	N/A
May 22, 2026	Canaccord Genuity	Buy	N/A
May 19, 2026	B of A Securities	Buy	N/A
May 19, 2026	Citigroup	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BMRN Stock Page